CoChat

Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases

Open access
MURATORI, P, MURATORI, L, GUIDI, M, MACCARIELLO, S, PAPPAS, G, FERRARI, R, GIONCHETTI, P, CAMPIERI, M, BIANCHI, F B · 2003 · Clinical and Experimental Immunology
Cited by 102

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

SUMMARY: Antibodies to the baker's yeast Saccharomyces cerevisiae (ASCA), recently proposed as a serological marker of Crohn's disease, have also been detected in other autoimmune disorders. The aim of this study was to determine prevalence and clinical significance of ASCA in autoimmune liver disease. The presence of IgG and IgA ASCA was evaluated using a commercially available immunoassay in 215 patients with autoimmune liver disease (primary biliary cirrhosis, PBC, 123 cases; autoimmune hepatitis, AIH, 67 cases; primary sclerosing cholangitis, PSC, 25 cases), 48 with inflammatory bowel disease and 19 healthy blood donors. Anti neutrophil cytoplasmic antibodies with the perinuclear pattern (p-ANCA) were assessed by indirect immunofluorescence in PSC patients. The main clinical and biochemical parameters between ASCA-positive and negative patients were analysed and compared. ASCA are predominant in Crohn's disease (70%); among liver patients, PSC and AMA-negative PBC show the highest ASCA prevalence (53% and 44%). In PBC ASCA correlate with higher levels of circulating IgA (P < 0·05). In PSC the detection of either ASCA or p-ANCA is neither associated with any clinical or biochemical feature, nor with an underlying inflammatory bowel disease. ASCA can not be considered an additional serological marker of autoimmune liver disease, but the possibility of detecting such a reactivity in autoimmune liver disorders should be considered; their correlation with elevated IgA in PBC suggests that ASCA may be an indirect sign of enhanced mucosal immunity; in PSC patients neither ASCA nor p-ANCA predict the occurrence of a concomitant inflammatory bowel disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2249.2003.02166.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 102

Metadata

Authors
MURATORI, P., MURATORI, L., GUIDI, M., MACCARIELLO, S., PAPPAS, G., FERRARI, R., GIONCHETTI, P., CAMPIERI, M., & BIANCHI, F. B.
Venue
Clinical and Experimental Immunology
Published
2003-05-29
Volume
132
Issue
3
Pages
473-476
ISSN
  • 0009-9104 (ISSN-L)
  • 1365-2249
OpenAlex
W2100684647
Cited by
102
References
1
FWCI
2.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. https://app.cochat.ai/papers/10.1046/j.1365-2249.2003.02166.x
The paper
MURATORI, P., MURATORI, L., GUIDI, M., MACCARIELLO, S., PAPPAS, G., FERRARI, R., GIONCHETTI, P., CAMPIERI, M., & BIANCHI, F. B. (2003). Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clinical and Experimental Immunology. https://doi.org/10.1046/j.1365-2249.2003.02166.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.